Status:
TERMINATED
Anecortave Acetate Risk-Reduction Trial (AART)
Lead Sponsor:
Alcon Research
Conditions:
AMD
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
The purpose of this study was to demonstrate that Anecortave Acetate for Depot Suspension (15 mg or 30 mg) is safe and effective in arresting the progression of non-exudative (dry) age-related macular...
Eligibility Criteria
Inclusion
- Dry AMD in study eye, Wet AMD in non-study eye;
- Other protocol-defined inclusion criteria may apply.
Exclusion
- Under 50;
- Other protocol-defined exclusion criteria may apply.
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00333216
Start Date
May 1 2005
End Date
December 1 2008
Last Update
November 28 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Contact Alcon Call Center for Trial Locations
Fort Worth, Texas, United States, 76134